{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:06:57Z","timestamp":1791166017388,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HU22C0138"],"award-info":[{"award-number":["HU22C0138"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HR22C1411"],"award-info":[{"award-number":["HR22C1411"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI22C0977"],"award-info":[{"award-number":["HI22C0977"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HR22C1411"],"award-info":[{"award-number":["HR22C1411"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1C1C2011227"],"award-info":[{"award-number":["2022R1C1C2011227"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nigrostriatal dopaminergic degeneration is a pathological hallmark of dementia with Lewy bodies (DLB). To identify the subregional dopamine transporter (DAT) uptake patterns that improve the diagnostic accuracy of DLB, we analyzed N-(3-[<jats:sup>18<\/jats:sup>F] fluoropropyl)-2\u03b2-carbomethoxy-3\u03b2-(4-iodophenyl)-nortropane (FP-CIT) PET in 51 patients with DLB, in 36 patients with mild cognitive impairment with Lewy body (MCI-LB), and in 40 healthy controls (HCs). In addition to a high affinity for DAT, FP-CIT show a modest affinity to serotonin or norepinephrine transporters. Specific binding ratios (SBRs) of the nigrostriatal subregions were transformed to age-adjusted z-scores (zSBR) based on HCs. The diagnostic accuracy of subregional zSBRs were tested using receiver operating characteristic (ROC) curve analyses separately for MCI-LB and DLB versus HCs. Then, the effect of subregional zSBRs on the presence of clinical features and gray matter (GM) density were evaluated in all patients with MCI-LB or DLB as a group. ROC curve analyses showed that the diagnostic accuracy of DLB based on the zSBR of substantia nigra (area under the curve [AUC], 0.90) or those for MCI-LB (AUC, 0.87) were significantly higher than that based on the zSBR of posterior putamen for DLB (AUC, 0.72) or MCI-LB (AUC, 0.65). Lower zSBRs in nigrostriatal regions were associated with visual hallucination, severe parkinsonism, and cognitive dysfunction, while lower zSBR of substantia nigra was associated with widespread GM atrophy in DLB and MCI-LB patients. Taken together, our results suggest that evaluation of nigral DAT uptake may increase the diagnostic accuracy of DLB and MCI-LB than other striatal regions.<\/jats:p>","DOI":"10.1038\/s41531-023-00534-9","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T04:01:57Z","timestamp":1686283317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Substantia nigral dopamine transporter uptake in dementia with Lewy bodies"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-455X","authenticated-orcid":false,"given":"Young-gun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-3352","authenticated-orcid":false,"given":"Seun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungwon","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Woo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0187-8440","authenticated-orcid":false,"given":"Byoung Seok","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"534_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/35081564","volume":"2","author":"M Goedert","year":"2001","unstructured":"Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492\u2013501 (2001).","journal-title":"Nat. Rev. Neurosci."},{"key":"534_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"534_CR3","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","volume":"78","author":"Z Walker","year":"2007","unstructured":"Walker, Z. et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J. Neurol. Neurosurg. Psychiatry 78, 1176 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"534_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith, I. et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 6, 305\u2013313 (2007).","journal-title":"Lancet Neurol."},{"key":"534_CR5","doi-asserted-by":"publisher","unstructured":"McKeith, I. G. et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94, https:\/\/doi.org\/10.1212\/WNL.0000000000009323 (2020).","DOI":"10.1212\/WNL.0000000000009323"},{"key":"534_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1192\/bjp.bp.108.052050","volume":"194","author":"JT O\u2019Brien","year":"2009","unstructured":"O\u2019Brien, J. T. et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Brit J. Psychiat 194, 34\u201339 (2009).","journal-title":"Brit J. Psychiat"},{"key":"534_CR7","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/01.WNL.0000123248.39847.1D","volume":"62","author":"Z Walker","year":"2004","unstructured":"Walker, Z. et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease. Neurology 62, 1568\u20131572 (2004).","journal-title":"Neurology"},{"key":"534_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0000000000003512","volume":"88","author":"AJ Thomas","year":"2017","unstructured":"Thomas, A. J. et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology 88, 276\u2013283 (2017).","journal-title":"Neurology"},{"key":"534_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00401-019-02071-3","volume":"138","author":"A Raunio","year":"2019","unstructured":"Raunio, A. et al. Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85. Acta Neuropathol. 138, 771\u2013782 (2019).","journal-title":"Acta Neuropathol."},{"key":"534_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","volume":"117","author":"TG Beach","year":"2009","unstructured":"Beach, T. G. et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 117, 613\u2013634 (2009).","journal-title":"Acta Neuropathol."},{"key":"534_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1017\/S0033291718000995","volume":"49","author":"AJ Thomas","year":"2019","unstructured":"Thomas, A. J. et al. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol. Med. 49, 396\u2013402 (2019).","journal-title":"Psychol. Med."},{"key":"534_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1192\/bjp.2020.234","volume":"218","author":"G Roberts","year":"2021","unstructured":"Roberts, G. et al. Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. Br. J. Psychiatry 218, 276\u2013282 (2021).","journal-title":"Br. J. Psychiatry"},{"key":"534_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1","volume":"409","author":"BJ Ciliax","year":"1999","unstructured":"Ciliax, B. J. et al. Immunocytochemical localization of the dopamine transporter in human brain. J. Comp. Neurol. 409, 38\u201356 (1999).","journal-title":"J. Comp. Neurol."},{"key":"534_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1523\/JNEUROSCI.16-02-00436.1996","volume":"16","author":"MJ Nirenberg","year":"1996","unstructured":"Nirenberg, M. J. et al. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16, 436\u2013447 (1996).","journal-title":"J. Neurosci."},{"key":"534_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/289537a0","volume":"289","author":"A Cheramy","year":"1981","unstructured":"Cheramy, A., Leviel, V. & Glowinski, J. Dendritic release of dopamine in the substantia nigra. Nature 289, 537\u2013542 (1981).","journal-title":"Nature"},{"key":"534_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2017.11.039","volume":"385","author":"N Nicastro","year":"2018","unstructured":"Nicastro, N., Burkhard, P. R. & Garibotto, V. Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: A prospective study. J. Neurol. Sci. 385, 17\u201321 (2018).","journal-title":"J. Neurol. Sci."},{"key":"534_CR17","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s00259-016-3323-7","volume":"43","author":"F Nobili","year":"2016","unstructured":"Nobili, F., Arnaldi, D. & Morbelli, S. Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies? Eur. J. Nucl. Med Mol. I 43, 1056\u20131059 (2016).","journal-title":"Eur. J. Nucl. Med Mol. I"},{"key":"534_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s00259-016-3312-x","volume":"43","author":"JJ van der Zande","year":"2016","unstructured":"van der Zande, J. J., Booij, J., Scheltens, P., Raijmakers, P. G. & Lemstra, A. W. [123]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. Eur. J. Nucl. Med Mol. I 43, 1060\u20131066 (2016).","journal-title":"Eur. J. Nucl. Med Mol. I"},{"key":"534_CR19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/mds.25952","volume":"29","author":"AA Dijkstra","year":"2014","unstructured":"Dijkstra, A. A. et al. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson\u2019s disease. Mov. Disord. 29, 1244\u20131251 (2014).","journal-title":"Mov. Disord."},{"key":"534_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1523\/JNEUROSCI.15-03-01714.1995","volume":"15","author":"BJ Ciliax","year":"1995","unstructured":"Ciliax, B. J. et al. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15, 1714\u20131723 (1995).","journal-title":"J. Neurosci."},{"key":"534_CR21","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1093\/brain\/aws211","volume":"135","author":"SJ Colloby","year":"2012","unstructured":"Colloby, S. J., McParland, S., O\u2019Brien, J. T. & Attems, J. Neuropathological correlates of dopaminergic imaging in Alzheimer\u2019s disease and Lewy body dementias. Brain 135, 2798\u20132808 (2012).","journal-title":"Brain"},{"key":"534_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.410350421","volume":"35","author":"GR Uhl","year":"1994","unstructured":"Uhl, G. R. et al. Dopamine transporter messenger RNA in Parkinson\u2019s disease and control substantia nigra neurons. Ann. Neurol. 35, 494\u2013498 (1994).","journal-title":"Ann. Neurol."},{"key":"534_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.870120609","volume":"12","author":"JN Joyce","year":"1997","unstructured":"Joyce, J. N. et al. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with parkinson\u2019s, alzheimer\u2019s with parkinsonism, and alzheimer\u2019s disease. Mov. Disord. 12, 885\u2013897 (1997).","journal-title":"Mov. Disord."},{"key":"534_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/jnnp.65.2.164","volume":"65","author":"TJ Counihan","year":"1998","unstructured":"Counihan, T. J. & Penney, J. B. Jr Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson\u2019s disease brains. J. Neurol. Neurosurg. Psychiatry 65, 164\u2013169 (1998).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"534_CR25","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.110.078337","volume":"51","author":"M Ziebell","year":"2010","unstructured":"Ziebell, M. et al. Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I. J. Nucl. Med. 51, 1885\u20131891 (2010).","journal-title":"J. Nucl. Med."},{"key":"534_CR26","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/mds.23179","volume":"25","author":"F Roselli","year":"2010","unstructured":"Roselli, F. et al. Midbrain SERT in degenerative parkinsonisms: A 123I\u2010FP\u2010CIT SPECT study. Mov. Disord. 25, 1853\u20131859 (2010).","journal-title":"Mov. Disord."},{"key":"534_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0304-3940(87)90509-X","volume":"77","author":"D Wirtshafter","year":"1987","unstructured":"Wirtshafter, D., Stratford, T. R. & Asin, K. E. Evidence that serotonergic projections to the substantia nigra in the rat arise in the dorsal, but not the median, raphe nucleus. Neurosci. Lett. 77, 261\u2013266 (1987).","journal-title":"Neurosci. Lett."},{"key":"534_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.brainres.2016.01.036","volume":"1641","author":"CA Mejias-Aponte","year":"2016","unstructured":"Mejias-Aponte, C. A. Specificity and impact of adrenergic projections to the midbrain dopamine system. Brain Res. 1641, 258\u2013273 (2016).","journal-title":"Brain Res."},{"key":"534_CR29","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1093\/brain\/awz193","volume":"142","author":"MJ Betts","year":"2019","unstructured":"Betts, M. J. et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain 142, 2558\u20132571 (2019).","journal-title":"Brain"},{"key":"534_CR30","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000012444","volume":"97","author":"J Prasuhn","year":"2021","unstructured":"Prasuhn, J. et al. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease. Neurology 97, e1007\u2013e1016 (2021).","journal-title":"Neurology"},{"key":"534_CR31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.4103\/1673-5374.270297","volume":"15","author":"BA Bari","year":"2020","unstructured":"Bari, B. A., Chokshi, V. & Schmidt, K. Locus coeruleus-norepinephrine: basic functions and insights into Parkinson\u2019s disease. Neural Regen. Res. 15, 1006\u20131013 (2020).","journal-title":"Neural Regen. Res."},{"key":"534_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/pcn.13436","volume":"76","author":"M Mizutani","year":"2022","unstructured":"Mizutani, M., Sano, T., Ohira, M. & Takao, M. Neuropathological studies of serotonergic and noradrenergic systems in Lewy body disease patients with delusion or depression. Psychiatry Clin. Neurosci. 76, 459\u2013467 (2022).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"534_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2967\/jnumed.112.114025","volume":"54","author":"M Ziebell","year":"2013","unstructured":"Ziebell, M. et al. Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J. Nucl. Med. 54, 1072\u20131076 (2013).","journal-title":"J. Nucl. Med."},{"key":"534_CR34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/mds.22702","volume":"24","author":"F Roselli","year":"2009","unstructured":"Roselli, F. et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov. Disord. 24, 2097\u20132103 (2009).","journal-title":"Mov. Disord."},{"key":"534_CR35","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/ene.13390","volume":"24","author":"E Jaakkola","year":"2017","unstructured":"Jaakkola, E. et al. Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson\u2019s disease. Eur. J. Neurol. 24, 1341\u20131347 (2017).","journal-title":"Eur. J. Neurol."},{"key":"534_CR36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.11.1550","volume":"155","author":"A Abi-Dargham","year":"1998","unstructured":"Abi-Dargham, A. et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155, 761\u2013767 (1998).","journal-title":"Am. J. Psychiatry"},{"key":"534_CR37","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.28484","volume":"36","author":"T Kuusimaki","year":"2021","unstructured":"Kuusimaki, T. et al. Increased Risk of Parkinson\u2019s Disease in Patients With Schizophrenia Spectrum Disorders. Mov. Disord. 36, 1353\u20131361 (2021).","journal-title":"Mov. Disord."},{"key":"534_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2215-0366(15)00540-4","volume":"3","author":"E Mouchlianitis","year":"2016","unstructured":"Mouchlianitis, E., McCutcheon, R. & Howes, O. D. Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. Lancet Psychiatry 3, 451\u2013463 (2016).","journal-title":"Lancet Psychiatry"},{"key":"534_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1176\/appi.neuropsych.19110316","volume":"32","author":"A Powell","year":"2020","unstructured":"Powell, A., Ireland, C. & Lewis, S. J. G. Visual Hallucinations and the Role of Medications in Parkinson\u2019s Disease: Triggers, Pathophysiology, and Management. J. Neuropsychiatry Clin. Neurosci. 32, 334\u2013343 (2020).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"534_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.cub.2017.12.059","volume":"28","author":"CM Cassidy","year":"2018","unstructured":"Cassidy, C. M. et al. A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine. Curr. Biol. 28, 503\u2013514.e504 (2018).","journal-title":"Curr. Biol."},{"key":"534_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jns.2017.03.040","volume":"377","author":"S Shimizu","year":"2017","unstructured":"Shimizu, S. et al. Comparison of diagnostic utility of semi-quantitative analysis for DAT-SPECT for distinguishing DLB from AD. J. Neurol. Sci. 377, 50\u201354 (2017).","journal-title":"J. Neurol. Sci."},{"key":"534_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/mds.26327","volume":"31","author":"FJ Siepel","year":"2016","unstructured":"Siepel, F. J. et al. Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. Mov. Disord. 31, 118\u2013125 (2016).","journal-title":"Mov. Disord."},{"key":"534_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/RLU.0000000000000602","volume":"40","author":"A Del Sole","year":"2015","unstructured":"Del Sole, A. et al. Correlation between 123I-FP-CIT brain SPECT and parkinsonism in dementia with Lewy bodies: caveat for clinical use. Clin. Nucl. Med. 40, 32\u201335 (2015).","journal-title":"Clin. Nucl. Med."},{"key":"534_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00259-016-3466-6","volume":"44","author":"K Kasanuki","year":"2017","unstructured":"Kasanuki, K. et al. 123) I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. Eur. J. Nucl. Med. Mol. Imaging 44, 358\u2013365 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"534_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/mds.22858","volume":"25","author":"JE Lee","year":"2010","unstructured":"Lee, J. E. et al. A comparison of gray and white matter density in patients with Parkinson\u2019s disease dementia and dementia with Lewy bodies using voxel-based morphometry. Mov. Disord. 25, 28\u201334 (2010).","journal-title":"Mov. Disord."},{"key":"534_CR46","doi-asserted-by":"publisher","first-page":"fcac013","DOI":"10.1093\/braincomms\/fcac013","volume":"4","author":"K Kantarci","year":"2022","unstructured":"Kantarci, K. et al. Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Commun. 4, fcac013 (2022).","journal-title":"Brain Commun."},{"key":"534_CR47","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/WNL.48.4.969","volume":"48","author":"MJ Bannon","year":"1997","unstructured":"Bannon, M. J. & Whitty, C. J. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 48, 969\u2013977 (1997).","journal-title":"Neurology"},{"key":"534_CR48","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neurobiolaging.2015.01.016","volume":"36","author":"V Kaasinen","year":"2015","unstructured":"Kaasinen, V. et al. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson\u2019s disease. Neurobiol. Aging 36, 1757\u20131763 (2015).","journal-title":"Neurobiol. Aging"},{"key":"534_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/(SICI)1096-9861(19990621)409:1<25::AID-CNE3>3.0.CO;2-E","volume":"409","author":"SY Ma","year":"1999","unstructured":"Ma, S. Y. et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J. Comp. Neurol. 409, 25\u201337 (1999).","journal-title":"J. Comp. Neurol."},{"key":"534_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neurobiolaging.2018.08.007","volume":"72","author":"YG Lee","year":"2018","unstructured":"Lee, Y. G. et al. Amyloid-beta-related and unrelated cortical thinning in dementia with Lewy bodies. Neurobiol. Aging 72, 32\u201339 (2018).","journal-title":"Neurobiol. Aging"},{"key":"534_CR51","unstructured":"Kang, Y., Jang, S. & Na, D. Seoul neuropsychological screening battery. 2nd ed (SNSB-II). Seoul: Human Brain Research & Consulting Co (2012)."},{"key":"534_CR52","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3346\/jkms.2010.25.7.1071","volume":"25","author":"H-J Ahn","year":"2010","unstructured":"Ahn, H.-J. et al. Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients. J. Korean Med Sci. 25, 1071\u20131076 (2010).","journal-title":"J. Korean Med Sci."},{"key":"534_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s13139-011-0110-z","volume":"45","author":"JK Oh","year":"2011","unstructured":"Oh, J. K. et al. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson\u2019s Disease. Nucl. Med Mol. Imaging 45, 255\u2013260 (2011).","journal-title":"Nucl. Med Mol. Imaging"},{"key":"534_CR54","doi-asserted-by":"crossref","unstructured":"Fonov, V., Coup\u00e9, P., Eskildsen, S., F. & Collins, L., D. Atrophy specific MRI brain template for Alzheimer\u2019s disease and Mild Cognitive Impairment. In Alzheimer\u2019s Association International Conference S58 France, 2011).","DOI":"10.1016\/j.jalz.2011.05.087"},{"key":"534_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1109\/42.906424","volume":"20","author":"Y Zhang","year":"2001","unstructured":"Zhang, Y., Brady, M. & Smith, S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans. Med Imaging. 20, 45\u201357 (2001).","journal-title":"IEEE Trans. Med Imaging."},{"key":"534_CR56","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroimage.2011.02.046","volume":"56","author":"B Patenaude","year":"2011","unstructured":"Patenaude, B., Smith, S. M., Kennedy, D. N. & Jenkinson, M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 56, 907\u2013922 (2011).","journal-title":"Neuroimage"},{"key":"534_CR57","doi-asserted-by":"publisher","first-page":"116189","DOI":"10.1016\/j.neuroimage.2019.116189","volume":"206","author":"ET Rolls","year":"2020","unstructured":"Rolls, E. T. et al. Automated anatomical labelling atlas 3. Neuroimage 206, 116189 (2020).","journal-title":"Neuroimage"},{"key":"534_CR58","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.neuroimage.2010.09.025","volume":"54","author":"BB Avants","year":"2011","unstructured":"Avants, B. B. et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54, 2033\u20132044 (2011).","journal-title":"Neuroimage"},{"key":"534_CR59","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/RLU.0000000000000794","volume":"40","author":"J Joutsa","year":"2015","unstructured":"Joutsa, J., Johansson, J. & Kaasinen, V. Is Occipital Cortex a Valid Reference Region in 123I-FP-CIT SPECT Imaging? Clin. Nucl. Med. 40, 615\u2013616 (2015).","journal-title":"Clin. Nucl. Med."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00534-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00534-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00534-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:04:50Z","timestamp":1686287090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00534-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00534-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}